Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors

Clinical Cancer Research

Volumn 12, Issue 4, 2006, Pages 1284-1291

  Hogge, Donna E ^a   Yalcintepe, Leman ^a   Wong, Siaw Hui ^a   Gerhard, Brigitte ^a   Frankel, Arthur E ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; DIPHTHERIA TOXIN; DIPHTHERIA TOXIN INTERLEUKIN 3 FUSION PROTEIN; HYBRID PROTEIN; INTERLEUKIN 3; INTERLEUKIN 3 RECEPTOR; RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOGENETICS; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL;

ADOLESCENT; ADULT; AGED; CELL SURVIVAL; DIPHTHERIA TOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION; HUMANS; INTERLEUKIN-3; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MUTATION; PROTEIN SUBUNITS; RECEPTORS, INTERLEUKIN-3; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; SEQUENCE DELETION; TUMOR STEM CELLS;

EID: 33644755626     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2070     Document Type: Article

References (40)

1. Rowe JM, Andersen J, Cassileth PA, Oken MM, Bennett JM, Wiernik PH. Clinical trials of adults with acute myelogenous leukemia: experience of the Eastern Cooperative Oncology Group. In: Hiddemann W, Buchner T, Wormann B, et al., editors. Acute L. Berlin (Germany): Springer-Verlag; 1994. p. 542.
2. Bennett JM, Young ML, Andersen JW, et al. Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience. Cancer 1997;80:2205-9.
3. Chang F, Steelman LS, Lee JT, et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003;17:1263-93.
4. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor α chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000;14:1777-84.
5. Feuring-Buske M, Frankel AE, Alexander RL, Gerhard B, Hogge DE. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res 2002;62:1730-6.
6. Alexander RL, Ramage J, Kucera GL, Caligiuri MA, Frankel AE. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Leuk Res 2001; 25:875-81.
7. Shultz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995; 154:180-91.
8. Testa U, Riccioni R, Militi S, et al. Elevated expression of IL-3Ra in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood 2002;100:2980-8.
9. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-6.
10. -DR. Blood 1998;92: 4325-35.
11. Stoetzer OJ, Nussler V, Darsow M, et al. Association of bcl-2, bax, bcl-xL and interleukin-1 β-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia 1996;10: S18-22.
12. Fitzgerald D, Pastan I. Targeted toxin therapy for the treatment of cancer. J Natl Cancer Inst 1989;81: 1455-63.
13. Frankel AE, Ramage J, Kiser M, Alexander R, Kucera G, Miller MS. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Eng 2000;13:575-81.
14. Sandvig K, Olsnes S. Rapid entry of nicked diphtheria toxin into cell at low pH. Characterization of the entry process and effects of low pH on the toxin molecule. J Biol Chem 1981;256:9068-76.
15. Draper RK, Simon MI. The entry of diphtheria toxin into the mammalian cell cytoplasm: evidence for lysosomal involvement. J Biol Chem 1980;87:849-54.
16. Honjo T, Nishizuka Y, Kato I, Hayaishi O. Adenosine diphosphate ribosylation of aminoacyl transferase II and inhibition of protein synthesis by diphtheria toxin. J Biol Chem 1971;246:4251-60.
17. Yamaizumi M, Mekada E, Uchida T, Okada Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 1978;15:245-50.
18. Murphy JR, Bishai W, Borowski M, Miyanohara A, Boyd J, Nagle S. Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria-toxin-related α-melanocyte-stimulating hormone fusion protein. Proc Natl Acad Sci U S A 1986;83: 8258-62.
19. Williams DP, Parker K, Bacha P, et al. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng 1991;1:493-8.
20. Chadwick DE, Williams DP, Niho Y, Murphy JR., Minden MD. Cytotoxicity of a recombinant diphtheria toxin-granulocyte colony-stimulating factor fusion protein on human leukemic blast cells. Leuk Lymphoma 1993;11:249-62.
21. Feuring-Buske M, Frankel A, Gerhard B, Hogge D. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells. Exp Hematol 2000;28:1390-400.
22. Frankel AE, McCubrey JA, Miller MS, et al. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia 2000; 14:576-85.
23. Lopez AF, Shannon MF, Barry S, et al. A human interleukin 3 analog with increased biological and binding activities. Proc Natl Acad Sci U S A 1992;89: 11842-6.
24. Klein BK, Shieh JJ, Grabbe E, Li X, Welply JK, McKearn JP. Receptor binding kinetics of human IL-3 variants with altered proliferative activity. Biochem Biophys Res Commun 2001;288:1244-9.
25. Liu TF, Urieto JO, Moore JE, et al. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity. Exp Hematol 2004;32: 277-81.
26. Ailles LE, Gerhard B, Kawagoe H, Hogge DE. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 1999;94:1761-72.
27. Ailles LE, Gerhard B, Hogge DE. Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines. Blood 1997;90:2555-64.
28. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-5.
29. Frankel AE, Hall PD, Burbage C, et al. Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein. Blood 1997; 90:3654-61.
30. Hogge DE, Lansdorp PM, Reid D, Gerhard B, Eaves CJ. Enhanced detection, maintenance and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human Steel factor, interleukin-3 and granulocyte colony-stimulating factor. Blood 1996;88:3765-73.
31. Verlinden SF, van Es HH, van Bekkum DW. Serial bone marrow sampling for long-term follow up of human hematopoiesis in NOD/SCID mice. Exp Hematol 1998;26:627-30.
32. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
33. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000;25:169-93.
34. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998;92:2322-33.
35. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96: 4075-83.
36. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003;101:3142-9.
37. Hogge DE, Feuring-Buske M, Gerhard B, Frankel AE. The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia. Leuk Res 2004;28: 1221-6.
38. Alexander RL, Kucera GL, Klein B, Frankel AE. In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Bioconjug Chem 2000;11:564-8.
39. Hogge DE, Willman CL, Kreitman RJ, et al. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein. Blood 1998;92:589-95.
40. Testa U, Riccioni R, Biffoni M, et al. Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression. Blood 2005;106: 2527-9.